Works about IMATINIB
Results: 3229
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 3, p. 583, doi. 10.1002/psp4.13299
- By:
- Publication type:
- Article
Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 634, doi. 10.3390/cancers17040634
- By:
- Publication type:
- Article
Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?
- Published in:
- Chemotherapy (0009-3157), 2025, v. 70, n. 1, p. 26, doi. 10.1159/000541936
- By:
- Publication type:
- Article
SUCCESSFUL SURGICAL RESECTION OF ADVANCED GASTROINTESTINAL STROMAL TUMOUR POST NEOADJUVENT THERAPY.
- Published in:
- Malaysian Journal of Medical Sciences, 2008, p. 87
- By:
- Publication type:
- Article
CHRONIC MYELOID LEUKAEMIA IN HUSM IN THE ERA OF TARGETED THERAPY.
- Published in:
- Malaysian Journal of Medical Sciences, 2007, v. 14, p. 100
- By:
- Publication type:
- Article
Kinase inhibitors in cancer therapy.
- Published in:
- Veterinary & Comparative Oncology, 2004, v. 2, n. 4, p. 177, doi. 10.1111/j.1476-5810.2004.00059.x
- By:
- Publication type:
- Article
Good Things Take Time: Tiwary–Seeliger Collaboration for Predictive Pharmacodynamics.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 23, p. 1, doi. 10.1002/ange.202303339
- Publication type:
- Article
Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction.
- Published in:
- Clinical & Experimental Nephrology, 2012, v. 16, n. 2, p. 310, doi. 10.1007/s10157-011-0543-9
- By:
- Publication type:
- Article
Effects of Chemotherapy during Pregnancy on the Placenta.
- Published in:
- Pediatric & Developmental Pathology, 2009, v. 12, n. 1, p. 35, doi. 10.2350/08-03-0435.1
- By:
- Publication type:
- Article
Clinical significance of surgical intervention for imatinib-resistant gastrointestinal stromal tumors in the era of multiple tyrosine kinase inhibitors.
- Published in:
- Surgery Today, 2021, v. 51, n. 9, p. 1506, doi. 10.1007/s00595-021-02241-5
- By:
- Publication type:
- Article
Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.
- Published in:
- Surgery Today, 2019, v. 49, n. 6, p. 460, doi. 10.1007/s00595-018-1737-5
- By:
- Publication type:
- Article
Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.
- Published in:
- Surgery Today, 2017, v. 47, n. 10, p. 1188, doi. 10.1007/s00595-017-1524-8
- By:
- Publication type:
- Article
Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.
- Published in:
- Functional & Integrative Genomics, 2017, v. 17, n. 2/3, p. 263, doi. 10.1007/s10142-016-0520-1
- By:
- Publication type:
- Article
Effect of Prolonged c-Kit Receptor Inhibition by Imatinib Mesylate on the Uterine Contractility of Pregnant Rabbits.
- Published in:
- Gynecologic & Obstetric Investigation, 2008, v. 65, n. 2, p. 108, doi. 10.1159/000109080
- By:
- Publication type:
- Article
Hydrogel Nanoparticles of Chitosan—Folic-Acid Conjugate with Imatinib Methanesulfonate.
- Published in:
- Pharmaceutical Chemistry Journal, 2018, v. 52, n. 2, p. 127, doi. 10.1007/s11094-018-1777-6
- By:
- Publication type:
- Article
Microencapsulation of Imatinib Methanesulfonate.
- Published in:
- Pharmaceutical Chemistry Journal, 2017, v. 51, n. 6, p. 486, doi. 10.1007/s11094-017-1639-7
- By:
- Publication type:
- Article
Comparative pharmacokinetics and bioequivalence of two imatinib formulations as film-coated tablets, 400 mg.
- Published in:
- Pharmaceutical Chemistry Journal, 2013, v. 46, n. 10, p. 622, doi. 10.1007/s11094-013-0857-x
- By:
- Publication type:
- Article
Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib.
- Published in:
- Glycobiology, 2016, v. 26, n. 4, p. 343, doi. 10.1093/glycob/cwv107
- By:
- Publication type:
- Article
Identifying Risk Factors Associated with Survival and Drug- Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 3, p. 292, doi. 10.14744/ejmi.2022.14970
- By:
- Publication type:
- Article
Imatinib-induced maculopapular drug rash.
- Published in:
- Indian Journal of Drugs in Dermatology, 2023, v. 9, n. 2, p. 82, doi. 10.4103/ijdd.ijdd_40_21
- By:
- Publication type:
- Article
Discoid lupus erythematosus like lesions after imatinib therapy: A rare case report.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Imatinib Mesylate-Induced Palmoplantar Keratoderma.
- Published in:
- Indian Journal of Drugs in Dermatology, 2021, v. 7, n. 1, p. 49, doi. 10.4103/ijdd.ijdd_17_20
- By:
- Publication type:
- Article
Imatinib Mesylate-Induced Psoriasiform Drug Reaction: A Case of Dose-Dependent Cutaneous Toxicity.
- Published in:
- Indian Journal of Drugs in Dermatology, 2021, v. 7, n. 1, p. 46, doi. 10.4103/ijdd.ijdd_25_20
- By:
- Publication type:
- Article
A systematic study of hematological and molecular response to generic imatinib mesylate therapy in patients of chronic myeloid leukemia.
- Published in:
- Indian Journal of Basic & Applied Medical Research, 2020, v. 9, n. 3, p. 95, doi. 10.36848/IJBAMR/2020/12225.51560
- By:
- Publication type:
- Article
Privileged fragment-based design, synthesis and in vitro antitumor activity of imatinib analogues.
- Published in:
- Turkish Journal of Chemistry, 2023, v. 47, n. 2, p. 426, doi. 10.55730/1300-0527.3549
- By:
- Publication type:
- Article
Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives as anticancer agents.
- Published in:
- Turkish Journal of Chemistry, 2022, v. 46, n. 1, p. 86, doi. 10.3906/kim-2107-23
- By:
- Publication type:
- Article
Synthesis and cytotoxicity evaluation of [(2,4-dichlorophenoxy)methyl]-5-aryl-1,3,4-oxadiazole/4H-1,2,4-triazole analogues.
- Published in:
- Turkish Journal of Chemistry, 2018, v. 42, n. 5, p. 1334, doi. 10.3906/kim-1803-25
- By:
- Publication type:
- Article
Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 6, p. 378, doi. 10.1093/jnci/djt029
- By:
- Publication type:
- Article
FDA Updates Gleevec Label for GIST Patients.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 5, p. 346, doi. 10.1093/jnci/djs148
- By:
- Publication type:
- Article
IN THIS ISSUE.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 525, doi. 10.1093/jnci/djr116
- Publication type:
- Article
CML Patients Taking Imatinib Have Similar Mortality Rates to People in General Population.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. NP, doi. 10.1093/jnci/djr127
- Publication type:
- Article
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 553, doi. 10.1093/jnci/djr060
- By:
- Publication type:
- Article
Imatinib for Chronic Myeloid Leukemia: The Impact of Its Effectiveness and Long-term Side Effects.
- Published in:
- 2011
- By:
- Publication type:
- Editorial
Drug Developers Unveil Strategies Aimed at Imatinib-Resistant CML.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 9, p. 593, doi. 10.1093/jnci/djq163
- By:
- Publication type:
- Article
T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 3, p. 194, doi. 10.1093/jnci/djn477
- By:
- Publication type:
- Article
Mutation-Negative Leukemia and Persistent Activation of LYN Kinase.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 13, p. 926, doi. 10.1093/jnci/djn188
- By:
- Publication type:
- Article
Disease Progression in Some Cancers May Be Due to Low Blood Levels of Targeted Therapies.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 13, p. 912, doi. 10.1093/jnci/djn230
- By:
- Publication type:
- Article
Persistent LYN Signaling in Imatinib-Resistant, BCR-ABL—lndependent Chronic Myelogenous Leukemia.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
Imatinib-Resistant Leukemia and LYN Kinase.
- Published in:
- 2008
- Publication type:
- Abstract
Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 9, p. 680, doi. 10.1093/jnci/djk150
- By:
- Publication type:
- Article
In Brief.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 17, p. 1179, doi. 10.1093/jnci/djj385
- Publication type:
- Article
Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 8, p. 562, doi. 10.1093/jnci/djj137
- By:
- Publication type:
- Article
New Drug May Overcome Imatinib Resistance.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2004, v. 96, n. 15, p. 1127
- By:
- Publication type:
- Article
Researchers Discover New Kinase Inhibitor That Targets Leukemia.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2004, v. 96, n. 10, p. 734
- By:
- Publication type:
- Article
As targeted therapies evolve, challenges remain.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
- Published in:
- 2004
- By:
- Publication type:
- journal article
From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
- Published in:
- 2003
- By:
- Publication type:
- journal article
RESPONSE.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2003, v. 95, n. 14, p. 1088
- By:
- Publication type:
- Article
Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
- Published in:
- 2003
- By:
- Publication type:
- commentary
Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2023, v. 38, n. 1, p. 1, doi. 10.1080/14756366.2023.2189097
- By:
- Publication type:
- Article